Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $30,925 | 4 | 75.3% |
| Unspecified | $10,000 | 3 | 24.3% |
| Food and Beverage | $149.43 | 1 | 0.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Bioscience Inc. | $30,925 | 4 | $0 (2023) |
| Ipsen Pharma SAS | $10,000 | 3 | $0 (2024) |
| Seattle Genetics, Inc. | $149.43 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,375 | 1 | Ipsen Pharma SAS ($4,375) |
| 2023 | $36,550 | 6 | Ipsen Bioscience Inc. ($30,925) |
| 2017 | $149.43 | 1 | Seattle Genetics, Inc. ($149.43) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/19/2024 | Ipsen Pharma SAS | — | — | Cash or cash equivalent | $4,375.00 | Research |
| Study: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged greater than or equal to 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. | ||||||
| 11/17/2023 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $8,250.00 | General |
| 11/17/2023 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $7,675.00 | General |
| 11/17/2023 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| 11/17/2023 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| 03/10/2023 | Ipsen Pharma SAS | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged greater than or equal to 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. | ||||||
| 03/10/2023 | Ipsen Pharma SAS | — | — | Cash or cash equivalent | $2,625.00 | Research |
| Study: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged greater than or equal to 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. | ||||||
| 04/07/2017 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $149.43 | General |
| Category: Not Applicable | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged greater than or equal to 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. | Ipsen Pharma SAS | $10,000 | 3 |
About Dr. Giannoula Klement, MD
Dr. Giannoula Klement, MD is a Pediatric Hematology-Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174579718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Giannoula Klement, MD has received a total of $41,074 in payments from pharmaceutical and medical device companies, with $4,375 received in 2024. These payments were reported across 8 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($30,925).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Boston, MA
- Active Since 05/25/2006
- Last Updated 09/01/2009
- Taxonomy Code 2080P0207X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174579718
Products in Payments
- ADCETRIS (Biological) $149.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Boston
Mr. Alan Dandrea, Md, MD
Pediatric Hematology-Oncology — Payments: $826,972
Dr. Leslie Kean, Md/Phd, MD/PHD
Pediatric Hematology-Oncology — Payments: $326,453
Todd Golub, M.d, M.D
Pediatric Hematology-Oncology — Payments: $247,953
Dr. Stacy Croteau, Md, MD
Pediatric Hematology-Oncology — Payments: $219,942
Matthew Heeney, Md, MD
Pediatric Hematology-Oncology — Payments: $201,707
Christine Duncan, M.d, M.D
Pediatric Hematology-Oncology — Payments: $74,023